• Johnson & Johnson outlined more than 30 hematology abstracts scheduled for presentation at European Hematology Association 2026 Congress in Stockholm on June 11-14.
• Phase 3 MonumenTAL-3 results will be presented in a plenary session, testing TALVEY in combination with DARZALEX FASPRO, with or without pomalidomide, in earlier-line relapsed or refractory multiple myeloma.
• Pivotal Phase 2/3 ENERGY results will be presented in an oral session, positioning investigational IMAAVY (nipocalimab) as a potential first approved treatment for warm autoimmune hemolytic anemia, with study readouts focused on improving anemia-related outcomes and fatigue versus placebo.
• FDA granted Priority Review for IMAAVY in warm autoimmune hemolytic anemia, raising near-term regulatory stakes for a program that could open a new commercial segment beyond its existing generalized myasthenia gravis use.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief on May 12, 2026, and is solely responsible for the information contained therein.